Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

Abstract

Recombinant human IgG antibodies (hIgGs) completely devoid of binding to Fcγ receptors (FcγRs) and complement protein C1q, and thus with abolished immune effector functions, are of use for various therapeutic applications in order to reduce FcγR activation and Fc-mediated toxicity. Fc engineering approaches described to date only partially achieve this goal or employ a large number of mutations, which may increase the risk of anti-drug antibody generation. We describe here two new, engineered hIgG Fc domains, hIgG1-P329G LALA and hIgG4-P329G SPLE, with completely abolished FcγR and C1q interactions, containing a limited number of mutations and with unaffected FcRn interactions and Fc stability. Both 'effector-silent' Fc variants are based on a novel Fc mutation, P329G that disrupts the formation of a proline sandwich motif with the FcγRs. As this motif is present in the interface of all IgG Fc/FcγR complexes, its disruption can be applied to all human and most of the other mammalian IgG subclasses in order to create effector silent IgG molecules.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/protein/gzw040

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 2

  1. Cheung, 2014, Invest. Ophthalmol. Vis. Sci., 55, 1174
  2. Gillies, 1999, Cancer Res., 59, 2159

Cited by

See all 439

Metadata

Authors
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E.
Affiliations
  • Roche Pharma AG (Germany) (DE)
  • F. Hoffmann-La Roche AG (CH)
Corresponding author
Mössner, Ekkehard
Venue
Protein Engineering Design and Selection
Published
2016-08-29
Volume
29
Issue
10
Pages
457-466
ISSN
  • 0269-2139 (ISSN-L)
  • 1741-0126
  • 1741-0134
OpenAlex
W2509039973
Cited by
425
References
51
Citations by year
2026: 71 · 2025: 63 · 2024: 65 · 2023: 48 · 2022: 47 · 2021: 45 · 2020: 35 · 2019: 24 · 2018: 13 · 2017: 13 · 2016: 1
FWCI
14.76
Type
journal article
Language
en
Open access
closed
Locations
  • Protein Engineering Design and Selection (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Keywords
Fc engineering, IgG1, IgG4, Fc gamma receptor, C1q binding, FcRn binding, anti-drug antibodies, immune effector functions
MeSH terms
Binding Sites, Cell Line, Glycosylation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Membrane Glycoproteins, Models, Molecular, Mutation, Platelet Aggregation, Polymorphism, Genetic, Receptors, Complement, Protein Engineering, Conserved Sequence, Protein Structure, Secondary, Receptors, IgG

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. https://app.cochat.ai/papers/10.1093/protein/gzw040
The paper
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umaña, P., & Mössner, E. (2016). Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Engineering Design and Selection. https://doi.org/10.1093/protein/gzw040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.